Omeros (OMER) Projected to Post Earnings on Monday

Omeros (NASDAQ:OMER) will likely be issuing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect the company to announce earnings of ($0.55) per share and revenue of $40.1490 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

Omeros Stock Performance

Shares of NASDAQ:OMER opened at $9.88 on Friday. The company has a 50-day simple moving average of $11.48 and a 200 day simple moving average of $9.60. The company has a market capitalization of $700.49 million, a P/E ratio of -4.89 and a beta of 2.45. Omeros has a 52-week low of $2.95 and a 52-week high of $17.65.

Insider Activity

In related news, CAO David J. Borges sold 30,000 shares of the firm’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total value of $369,300.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 12.90% of the company’s stock.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new position in Omeros in the 1st quarter valued at about $357,000. XTX Topco Ltd bought a new stake in shares of Omeros during the 2nd quarter worth approximately $191,000. Invesco Ltd. lifted its holdings in shares of Omeros by 34.1% during the 2nd quarter. Invesco Ltd. now owns 116,688 shares of the biopharmaceutical company’s stock worth $350,000 after acquiring an additional 29,644 shares during the period. Marshall Wace LLP boosted its position in shares of Omeros by 15.1% during the 2nd quarter. Marshall Wace LLP now owns 741,376 shares of the biopharmaceutical company’s stock worth $2,224,000 after acquiring an additional 97,224 shares in the last quarter. Finally, Sei Investments Co. acquired a new stake in shares of Omeros during the 2nd quarter worth approximately $40,000. Institutional investors own 48.79% of the company’s stock.

Analyst Upgrades and Downgrades

OMER has been the subject of a number of recent analyst reports. HC Wainwright raised their price objective on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. D. Boral Capital reissued a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, January 27th. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.33.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.